A 62-year-old male presented with generalized weakness and abdominal discomfort since the past 4 months; there were no other significant complaints. On examination, the patient was pale and his abdominal palpitation revealed an enlarged, firm, nontender splenomegaly 10-cm below the costal margin. His complete blood count results were as follows: white blood cell (WBC) count, 3.0 × 10^9^/L; red blood cell count, 2.37 × 10^12^/L; hemoglobin, 6.7 g/dl; and platelet count, 30 × 10^9^/L. A peripheral blood smear demonstrated normocytic normochromic red cells with a WBC differential count of 22% polymorphs, 70% lymphocytes, 2% monocytes, 1% eosinophils and 5% atypical cells \[Figure [1a](#F1){ref-type="fig"} and [b](#F1){ref-type="fig"}\]. Bone marrow aspiration was not possible ("dry tap"). The hematoxylin and eosin staining of the trephine bone marrow biopsy showed an infiltration by cells with a characteristic "fried egg" appearance of the cytoplasm \[[Figure 2](#F2){ref-type="fig"}\].

![(a and b) Peripheral blood smear showing an atypical cell with multiple cytoplasmic projections](SJMMS-7-55-g001){#F1}

![Hematoxylin and eosin staining of the bone marrow biopsy](SJMMS-7-55-g002){#F2}

QUESTIONS {#sec1-1}
=========

What are the atypical cells seen in [Figure 1](#F1){ref-type="fig"}?What are the confirmatory tests and what is the final diagnosis?

ANSWERS {#sec1-2}
=======

Hairy cellsThe final diagnosis is hairy cell leukemia (HCL). Immunophenotyping and immunohistochemistry analysis are critical in establishing this diagnosis.

DISCUSSION {#sec1-3}
==========

HCL is an uncommon chronic lymphoid leukemia that constitutes approximately 2% of all adult leukemias.\[[@ref1]\] HCL affects males more commonly than females (male: female ratio = 4:1) and the median age at diagnosis is 50--59 years.\[[@ref2]\] In general, HCL patients present with splenomegaly (\>3 cm below the costal margin) and pancytopenia without lymphadenopathy and with the associated fatigue, abdominal pain in the left upper quadrant, fever and/or infections.\[[@ref1][@ref2]\]

Identification of the hairy cells can be made by careful examination of the peripheral blood smears and assessment of the complete blood count, as monocytopenia is characteristically observed.\[[@ref1][@ref2]\] Hairy cells are lymphoid cells having an oval or bean-shaped nucleus with loose chromatin and abundant pale blue cytoplasm with circumferential hair-like projections.\[[@ref2][@ref3]\] The characteristic immunophenotypic profile includes positive expression of CD19, CD20, CD22 and CD200 antibodies as well as positivity for at least three of the following antibodies: CD11c, CD25, CD103 and CD123. In contrast, for CD5, CD10, CD23, CD27 and CD79b antibodies, hairy cells are negative or dim.\[[@ref1][@ref3]\]

A bone marrow examination is necessary to understand the extent of infiltration as well as to assess response to treatment; however, bone marrow aspiration is extremely difficult to obtain, as it is usually a "dry tap."\[[@ref3]\] Nonetheless, a bone marrow trephine biopsy would help determine the degree of infiltration and the presence of BRAF V600E somatic mutation, which is present in about 90% of HCL cases. Immunohistochemical stains using CD20, CD76, annexin A1 and tartrate-resistant acid phosphatase stain would support HCL diagnosis and highlight the extent of lymphoid infiltrates.\[[@ref1][@ref3]\] The differential diagnosis of HCL includes the HCL variant, splenic marginal zone lymphoma, chronic lymphocytic leukemia, prolymphocytic leukemia and mantle cell lymphoma.\[[@ref1]\] However, with the support of immunophenotyping and immunohistochemistry, HCL diagnosis can be established.

Over the decades, HCL treatment modality has changed from splenectomy to recombinant interferon-alpha to adenosine deaminase inhibitor deoxycoformycin (pentostatin). However, purine analogs are the mainstay of HCL therapy, of which 2-chlorodeoxyadenosine (cladribine) is the most active with very high response rates.\[[@ref3][@ref4]\]
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